Emily Pimblett sold $9,741 of CLYM
CHIEF ACCOUNTING OFFICER at Eliem Therapeutics, Inc.. 1,191 shares at an average of $8.18, traded Sep 20, 2024, filed Sep 20, 2024.
Score components
- +15RoleOfficer
- 0Trade size$10k at market
- +5Share of holdings soldSold 14% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -40.5%, 3m -76.9%, 6m -84.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-108582, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 18, 2024 | MOption exercise Common Stock10b5-1 | +5,000 | - | - | 8,755 | Sep 20, 2024 |
| Sep 20, 2024 | SOpen-market sale Common Stock10b5-1 | -1,182 | $8.18 | $9,669 | 7,573 | Sep 20, 2024 |
| Sep 20, 2024 | SOpen-market sale Common Stock10b5-1 | -9 | $8.06 | $73 | 7,564 | Sep 20, 2024 |
| Sep 18, 2024 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -5,000 | $0.00 | $0 | 30,000 | Sep 20, 2024 |
Related signals
Other insiders at Eliem Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Eliem Therapeutics, Inc. | Stephen Basil Thomas director | $1.4M 100,000 shares | -18% | |
| 16Weak | Eliem Therapeutics, Inc. | Aoife Brennan President and CEO | $407k 30,902 shares | -26% | |
| 15Weak | Eliem Therapeutics, Inc. | Stephen Basil Thomas director | $350k 50,000 shares | -24% | |
| 23Weak | Eliem Therapeutics, Inc. | Stephen Basil Thomas director | $529k 100,000 shares | -33% | |
| 14Weak | CLYMbuy Eliem Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $25k 7,111 shares | +0% | |
| 39Weak | CLYMbuy Eliem Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $755k 314,561 shares | +10% | |
| 13Weak | Eliem Therapeutics, Inc. | Aoife Brennan President and CEO | $25k 20,618 shares | -30% | |
| 0Weak | Eliem Therapeutics, Inc. | Emily Pimblett SVP, Finance & CAO | $1,540 1,242 shares | -6% | |
| 0Weak | Eliem Therapeutics, Inc. | Emily Pimblett SVP, Finance & CAO | $1,571 1,199 shares | -7% | |
| 0Weak | Eliem Therapeutics, Inc. | Emily Pimblett CHIEF ACCOUNTING OFFICER | $2,495 1,235 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.